APC-activated Long Noncoding RNA Inhibits Colorectal Carcinoma Pathogenesis Through Reduction of Exosome Production

Feng-Wei Wang,Chen-Hui Cao,Kai Han,Yong-Xiang Zhao,Mu-Yan Cai,Zhi-Cheng Xiang,Jia-Xing Zhang,Jie-Wei Chen,Li-Ping Zhong,Yong Huang,Su-Fang Zhou,Xiao-Han Jin,Xin-Yuan Guan,Rui-Hua Xu,Dan Xie
DOI: https://doi.org/10.1172/jci122478
IF: 19.456
2021-01-01
Journal of Clinical Investigation
Abstract:The adenomatous polyposis coli (APC) gene plays a pivotal role in the pathogenesis of colorectal carcinoma (CRC) but remains a challenge for drug development. Long noncoding RNAs (lncRNAs) are invaluable in identifying cancer pathologies and providing therapeutic options for patients with cancer. Here, we identified a lncRNA (lncRNA-APC1) activated by APC through lncRNA microarray screening and examined its expression in a large cohort of CRC tissues. A decrease in lncRNA-APC1 expression was positively associated with lymph node and/or distant metastasis, a more advanced clinical stage, as well as a poor prognosis for patients with CRC. Additionally, APC could enhance lncRNA-APC1 expression by suppressing the enrichment of PPAR alpha on the lncRNA-APC1 promoter. Furthermore, enforced lncRNA-APC1 expression was sufficient to inhibit CRC cell growth, metastasis, and tumor angiogenesis by suppressing exosome production through the direct binding of Rab5b mRNA and a reduction of its stability. Importantly, exosomes derived from lncRNA-APC1-silenced CRC cells promoted angiogenesis by activating the MAPK pathway in endothelial cells, and, moreover, exosomal Wnt1 largely enhanced CRC cell proliferation and migration through noncanonicial Wnt signaling. Collectively, lncRNA-APC1 is a critical lncRNA regulated by APC in the pathogenesis of CRC. Our findings suggest that an APC-regulated lncRNA-APC1 program is an exploitable therapeutic approach for the treatment of patients with CRC.
What problem does this paper attempt to address?